

# Desmond Curran

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5947777/publications.pdf>

Version: 2024-02-01

61  
papers

2,617  
citations

361045

20  
h-index

197535

49  
g-index

62  
all docs

62  
docs citations

62  
times ranked

2952  
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term efficacy data for the recombinant zoster vaccine: impact on public health and cost effectiveness in Germany. <i>Human Vaccines and Immunotherapeutics</i> , 2024, 17, 5296-5303.	1.4	8
2	Impact of respiratory syncytial virus disease on quality of life in adults aged ≥50 years: A qualitative patient experience cross-sectional study. <i>Influenza and Other Respiratory Viruses</i> , 2022, 16, 462-473.	1.5	11
3	A Cross-Sectional Concept Elicitation Study to Understand the Impact of Herpes Zoster on Patients' Health-Related Quality of Life. <i>Infectious Diseases and Therapy</i> , 2022, 11, 501.	1.8	6
4	Modeled impact of the COVID-19 pandemic and associated reduction in adult vaccinations on herpes zoster in the United States. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-5.	1.4	5
5	Meta-Regression of Herpes Zoster Incidence Worldwide. <i>Infectious Diseases and Therapy</i> , 2022, 11, 389-403.	1.8	20
6	Cost-Effectiveness Analysis Update of the Adjuvanted Recombinant Zoster Vaccine in Japanese Older Adults. <i>Dermatology and Therapy</i> , 2022, 12, 1447-1467.	1.4	7
7	Impact of Reactogenicity After Two Doses of Recombinant Zoster Vaccine Upon Physical Functioning and Quality of Life: An Open Phase III Trial in Older Adults. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, 485-490.	1.7	7
8	Recombinant Zoster Vaccine Is Efficacious and Safe in Frail Individuals. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 744-752.	1.3	30
9	An algorithm to generate correlated input-parameters to be used in probabilistic sensitivity analyses. <i>Journal of Market Access &amp; Health Policy</i> , 2021, 9, 1857052.	0.8	0
10	Patient-reported outcomes in vaccines research: relevance for decision-making. <i>Human Vaccines and Immunotherapeutics</i> , 2021, , 1-8.	1.4	2
11	A systematic literature review of herpes zoster incidence worldwide. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 1714-1732.	1.4	66
12	Economic Burden and Impact on Quality of Life of Herpes Zoster in Spanish Adults Aged 50 Years or Older: A Prospective Cohort Study. <i>Advances in Therapy</i> , 2021, 38, 3325-3341.	1.3	19
13	Estimated Public Health Impact of the Recombinant Zoster Vaccine. <i>Mayo Clinic Proceedings Innovations, Quality &amp; Outcomes</i> , 2021, 5, 596-604.	1.2	3
14	Potential public health impact of the adjuvanted recombinant zoster vaccine among people aged 50 years and older in Beijing. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 3735-3746.	1.4	10
15	The potential public health impact of Herpes Zoster vaccination in the 65 years of age cohort in Italy. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 327-334.	1.4	6
16	Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2020, 26, 1567-1575.	0.5	1
17	Correspondence regarding Wilson et al., cost-effectiveness of a comprehensive immunization program serving high-risk, uninsured adults. <i>Preventive Medicine</i> , 2020, 133, 105973.	1.6	0
18	<sc>Burden of illness</sc> vaccine efficacy. <i>Pharmaceutical Statistics</i> , 2020, 19, 636-645.	0.7	4

#	ARTICLE	IF	CITATIONS
19	Quality of Life Impact of an Adjuvanted Recombinant Zoster Vaccine in Adults Aged 50 Years and Older. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2019, 74, 1231-1238.	1.7	36
20	Cost-effectiveness of the recombinant zoster vaccine in the German population aged ≥60 years old. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 34-44.	1.4	16
21	Recombinant Zoster Vaccine Significantly Reduces the Impact on Quality of Life Caused by Herpes Zoster in Adult Autologous Hematopoietic Stem Cell Transplant Recipients: A Randomized Placebo-Controlled Trial (ZOE-HSCT). <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2474-2481.	2.0	30
22	Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults. <i>Applied Health Economics and Health Policy</i> , 2019, 17, 723-732.	1.0	14
23	Evaluation of two frailty indices, with practical application in a vaccine clinical trial. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 2960-2968.	1.4	9
24	Public health impact model estimating the impact of introducing an adjuvanted recombinant zoster vaccine into the UK universal mass vaccination programme. <i>BMJ Open</i> , 2019, 9, e025553.	0.8	10
25	The Economic Burden and Impact on Quality of Life of Herpes Zoster and Postherpetic Neuralgia in Individuals Aged 50 Years or Older in Italy. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz007.	0.4	14
26	The comparative efficacy and safety of herpes zoster vaccines: A network meta-analysis. <i>Vaccine</i> , 2019, 37, 2896-2909.	1.7	31
27	Cost-Effectiveness of the Adjuvant Recombinant Zoster Vaccine in Japanese Adults Aged 65 Years and Older. <i>Dermatology and Therapy</i> , 2019, 9, 281-297.	1.4	8
28	Herpes zoster related healthcare burden and costs in immunocompromised (IC) and IC-free populations in England: an observational retrospective database analysis. <i>BMJ Open</i> , 2019, 9, e023502.	0.8	6
29	Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States who have been previously vaccinated with zoster vaccine live. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 765-771.	1.4	15
30	Burden of Herpes Zoster in the Japanese Population with Immunocompromised/Chronic Disease Conditions: Results from a Cohort Study Claims Database from 2005-2014. <i>Dermatology and Therapy</i> , 2019, 9, 117-133.	1.4	23
31	The Impact of Reactogenicity After the First Dose of Recombinant Zoster Vaccine on the Physical Functioning and Quality of Life of Older Adults: An Open-Label, Phase III Trial. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2019, 74, 1217-1224.	1.7	20
32	The Potential Public Health Impact of Herpes Zoster Vaccination of People Aged ≥50 Years in Japan: Results of a Markov Model Analysis. <i>Dermatology and Therapy</i> , 2018, 8, 269-284.	1.4	13
33	Incidence and costs of herpes zoster and postherpetic neuralgia in German adults aged ≥50 years: A prospective study. <i>Journal of Infection</i> , 2018, 76, 475-482.	1.7	32
34	Impact of Herpes Zoster and Post-Herpetic Neuralgia on Health-Related Quality of Life in Japanese Adults Aged 60 Years or Older: Results from a Prospective, Observational Cohort Study. <i>Clinical Drug Investigation</i> , 2018, 38, 29-37.	1.1	29
35	2488. The Impact of Reactogenicity After Administration of the Recombinant Zoster Vaccine Upon the Physical Functioning and Quality of Life of Older Adults. <i>Open Forum Infectious Diseases</i> , 2018, 5, S746-S747.	0.4	1
36	Impact of herpes zoster and postherpetic neuralgia on the quality of life of Germans aged 50 or above. <i>BMC Infectious Diseases</i> , 2018, 18, 496.	1.3	36

#	ARTICLE	IF	CITATIONS
37	Economic Burden of Herpes Zoster and Post-Herpetic Neuralgia in Adults 60 Years of Age or Older: Results from a Prospective, Physician Practice-Based Cohort Study in Kushiro, Japan. <i>Drugs - Real World Outcomes</i> , 2017, 4, 187-198.	0.7	13
38	Assessment of the potential public health impact of Herpes Zoster vaccination in Germany. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 2213-2221.	1.4	32
39	The temporal impact of aging on the burden of herpes zoster. <i>BMC Geriatrics</i> , 2017, 17, 30.	1.1	54
40	Response to publication by Hoshi SL et al.: Cost-effectiveness of varicella vaccine against herpes zoster and post-herpetic neuralgia for elderly in Japan. <i>Vaccine</i> , 2017, 35, 7079.	1.7	0
41	Quality-of-Life Impact of an Investigational Subunit-Adjuvanted Herpes Zoster Vaccine in Adults ≥50 Years of Age. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	2
42	Vaccine Timeliness. <i>Pediatric Infectious Disease Journal</i> , 2016, 35, 542-547.	1.1	17
43	The impact of assumptions regarding vaccine-induced immunity on the public health and cost-effectiveness of hepatitis A vaccination: Is one dose sufficient?. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2765-2771.	1.4	14
44	Response to publications by Heyward W et al. and Kuan R et al.: Clinical and cost-effectiveness analyses, respectively, of hepatitis B vaccination with Heplisav <sup>®</sup> , compared with Engerix-B <sup>®</sup> vaccine in adults. <i>Vaccine</i> , 2015, 33, 3161.	1.7	0
45	Estimating the Potential Public Health Impact of Introducing the HZ/su Vaccine in the US Population Aged ≥50 Years. <i>Open Forum Infectious Diseases</i> , 2015, 2, .	0.4	3
46	Budget constraint and vaccine dosing: a mathematical modelling exercise. <i>Cost Effectiveness and Resource Allocation</i> , 2014, 12, 3.	0.6	12
47	Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin. <i>European Journal of Cancer</i> , 2013, 49, 439-448.	1.3	58
48	Reply to the correspondence by Tourtier et al. on the original article entitled "Epidemiology of osteoporosis-related fractures in France: A literature review". <i>Joint Bone Spine</i> , 2011, 78, 104.	0.8	1
49	Épidémiologie des fractures liées à l'ostéoporose en France: revue de la littérature. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2010, 77, 579-585.	0.0	5
50	Epidemiology of osteoporosis-related fractures in France: A literature review. <i>Joint Bone Spine</i> , 2010, 77, 546-551.	0.8	51
51	Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial. <i>Quality of Life Research</i> , 2009, 18, 853-861.	1.5	33
52	Quality of Life in Head and Neck Cancer Patients After Treatment With High-Dose Radiotherapy Alone or in Combination With Cetuximab. <i>Journal of Clinical Oncology</i> , 2007, 25, 2191-2197.	0.8	225
53	Retrospective analysis of results of p(65)+Be neutron therapy for treatment of prostate adenocarcinoma at the cyclotron of Louvain-la-Leuve. Part II: Side effects and their influence on quality of life measured with QLQ-C30 of EORTC. <i>International Journal of Radiation Oncology Biology Physics</i> . 2004. 58. 1549-1561.	0.4	8
54	Sensitivity Analysis for Pattern Mixture Models. <i>Journal of Biopharmaceutical Statistics</i> , 2004, 14, 125-143.	0.4	16

#	ARTICLE	IF	CITATIONS
55	Prognostic Factors for Survival in Adult Patients With Cerebral Low-Grade Glioma. Journal of Clinical Oncology, 2002, 20, 2076-2084.	0.8	826
56	Strategies to fit pattern-mixture models. Biostatistics, 2002, 3, 245-265.	0.9	128
57	Multicollinearity in prognostic factor analyses using the EORTC QLQ-C30: identification and impact on model selection. Statistics in Medicine, 2002, 21, 3865-3884.	0.8	89
58	Treatment of Brain Metastases of Small-Cell Lung Cancer: Comparing Teniposide and Teniposide With Whole-Brain Radiotherapyâ€”A Phase III Study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group. Journal of Clinical Oncology, 2000, 18, 3400-3408.	0.8	223
59	Statistical analysis of quality of life with missing data in cancer clinical trials. , 1998, 17, 653-666.		87
60	Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: a randomised trial. Lancet, The, 1998, 351, 1677-1681.	6.3	81
61	Brain-only metastases of small cell lung cancer; efficacy of whole brain radiotherapy. An EORTC phase II study. Radiotherapy and Oncology, 1998, 46, 29-32.	0.3	91